197 related articles for article (PubMed ID: 32761352)
61. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics.
Miksys S; Rao Y; Hoffmann E; Mash DC; Tyndale RF
J Neurochem; 2002 Sep; 82(6):1376-87. PubMed ID: 12354285
[TBL] [Abstract][Full Text] [Related]
62. Regulation of cerebral CYP2D alters tramadol metabolism in the brain: interactions of tramadol with propranolol and nicotine.
Wang Q; Han X; Li J; Gao X; Wang Y; Liu M; Dong G; Yue J
Xenobiotica; 2015 Apr; 45(4):335-44. PubMed ID: 25387586
[TBL] [Abstract][Full Text] [Related]
63. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes.
Staack RF; Paul LD; Springer D; Kraemer T; Maurer HH
Biochem Pharmacol; 2004 Jan; 67(2):235-44. PubMed ID: 14698036
[TBL] [Abstract][Full Text] [Related]
64. Propranolol prevents life-threatening arrhythmias in LQT3 transgenic mice: implications for the clinical management of LQT3 patients.
Calvillo L; Spazzolini C; Vullo E; Insolia R; Crotti L; Schwartz PJ
Heart Rhythm; 2014 Jan; 11(1):126-32. PubMed ID: 24135497
[TBL] [Abstract][Full Text] [Related]
65. Interspecies metabolic diversity of harmaline and harmine in in vitro 11 mammalian liver microsomes.
Li S; Teng L; Liu W; Cheng X; Jiang B; Wang Z; Wang C
Drug Test Anal; 2017 May; 9(5):754-768. PubMed ID: 27377954
[TBL] [Abstract][Full Text] [Related]
66. Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism.
Gibbs JP; Hyland R; Youdim K
Drug Metab Dispos; 2006 Sep; 34(9):1516-22. PubMed ID: 16763018
[TBL] [Abstract][Full Text] [Related]
67. Usefulness of hepatocytes for evaluating the genetic polymorphism of CYP2D6 substrates.
Komura H; Iwaki M
Xenobiotica; 2005 Jun; 35(6):575-87. PubMed ID: 16192109
[TBL] [Abstract][Full Text] [Related]
68. The Involvement of PPARs in the Selective Regulation of Brain CYP2D by Growth Hormone.
Zhang F; Li J; Na S; Wu J; Yang Z; Xie X; Wan Y; Li K; Yue J
Neuroscience; 2018 May; 379():115-125. PubMed ID: 29555426
[TBL] [Abstract][Full Text] [Related]
69. High-affinity binding of beta-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain.
Miralles A; Esteban S; Sastre-Coll A; Moranta D; Asensio VJ; García-Sevilla JA
Eur J Pharmacol; 2005 Aug; 518(2-3):234-42. PubMed ID: 16061219
[TBL] [Abstract][Full Text] [Related]
70. Hypothermic effect of harmala alkaloid in rats: involvement of serotonergic mechanism.
Abdel-Fattah AF; Matsumoto K; Gammaz HA; Watanabe H
Pharmacol Biochem Behav; 1995 Oct; 52(2):421-6. PubMed ID: 8577810
[TBL] [Abstract][Full Text] [Related]
71. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.
Yu AM; Idle JR; Gonzalez FJ
Drug Metab Rev; 2004 May; 36(2):243-77. PubMed ID: 15237854
[TBL] [Abstract][Full Text] [Related]
72. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects.
Park JY; Shon JH; Kim KA; Jung HJ; Shim JC; Yoon YR; Cha IJ; Shin JG
J Clin Psychopharmacol; 2006 Apr; 26(2):135-42. PubMed ID: 16633141
[TBL] [Abstract][Full Text] [Related]
73. Central inhibition prevents the in vivo acute toxicity of harmine in mice.
Lv Y; Liang H; Li J; Li X; Tang X; Gao S; Zou H; Zhang J; Wang M; Xiao L
J Toxicol Sci; 2021; 46(6):289-301. PubMed ID: 34078836
[TBL] [Abstract][Full Text] [Related]
74. Specific binding of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl propyl) piperazine (GBR-12935), an inhibitor of the dopamine transporter, to human CYP2D6.
Hiroi T; Imaoka S; Chow T; Yabusaki Y; Funae Y
Biochem Pharmacol; 1997 Jun; 53(12):1937-9. PubMed ID: 9256169
[TBL] [Abstract][Full Text] [Related]
75. Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice.
Winter JC; Amorosi DJ; Rice KC; Cheng K; Yu AM
Pharmacol Biochem Behav; 2011 Sep; 99(3):311-5. PubMed ID: 21624387
[TBL] [Abstract][Full Text] [Related]
76. The effect of aprotinin on the harmine-induced tremor in lymphostatic encephalopathic and normal rats.
Back G; Seidel G
Eur J Pharmacol; 1975; 32(02):364-9. PubMed ID: 1080114
[TBL] [Abstract][Full Text] [Related]
77. CYP2D plays a major role in berberine metabolism in liver of mice and humans.
Guo Y; Li F; Ma X; Cheng X; Zhou H; Klaassen CD
Xenobiotica; 2011 Nov; 41(11):996-1005. PubMed ID: 21787170
[TBL] [Abstract][Full Text] [Related]
78. Propranolol hydroxylation and N-desisopropylation by cytochrome P4502D6: studies using the yeast-expressed enzyme and NADPH/O2 and cumene hydroperoxide-supported reactions.
Bichara N; Ching MS; Blake CL; Ghabrial H; Smallwood RA
Drug Metab Dispos; 1996 Jan; 24(1):112-8. PubMed ID: 8825198
[TBL] [Abstract][Full Text] [Related]
79. Rat brain CYP2D activity alters in vivo central oxycodone metabolism, levels and resulting analgesia.
McMillan DM; Miksys S; Tyndale RF
Addict Biol; 2019 Mar; 24(2):228-238. PubMed ID: 29266563
[TBL] [Abstract][Full Text] [Related]
80. Variable contribution of CYP2D6 to the N-dealkylation of S-(-)-propranolol by human liver microsomes.
Rowland K; Ellis SW; Lennard MS; Tucker GT
Br J Clin Pharmacol; 1996 Sep; 42(3):390-3. PubMed ID: 8877032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
